Clinical trials: Myeloma
Multiple Myeloma
Safety & Efficacy Study High Dose Evomela Injection for MA Conditioning in MM Patients With Autologous Transplantation
The purpose of this trial is to confirm the safety and efficacy of high-dose Melphalan HCL for Injection (Propylene Glycol-Free) as a myeloablative conditioning regimen in multiple myeloma patients (MM) undergoing autologous…
- Trial name
- NCT01660633
- Testing
- High-Dose Melphalan HCL for Injection (Propylene Glycol-Free), Autologous Transplantation
- Where
- 6 sites in United States
- Volunteers
- 61 people
- Sponsor
- Acrotech Biopharma Inc.
Advanced Solid Tumors, Relapsed/Refractory Non-Hodgkin Lymphoma
GIC-102, Intravenous Allogeneic NK Cells, in Subjects With Advanced Solid Cancers and R/R Hematologic Malignancies
This is a first-in-human trial to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor effects of GIC-102 in patients with advanced solid tumors, relapsed/refractory non-hodgkin lymphoma, and…
- Conditions
- Advanced Solid Tumors, Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Multiple Myeloma
- Trial name
- NCT05880043
- Testing
- GIC-102
- Where
- 4 sites in South Korea
- Volunteers
- 50 people
- Sponsor
- GI Cell, Inc.
Multiple Myeloma
A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM)
This is a first-in-human, open-label, uncontrolled, multi-center, monotherapy, dose-escalation and dose expansion study. Forimtamig will be administered to participants with r/r MM for whom no standard-of-care treatment exists or…
- Trial name
- NCT04557150
- Testing
- Forimtamig
- Where
- 20 sites in Australia, Belgium and 7 more
- Volunteers
- 225 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer, Lung Cancer
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
The goal of this study is to create a data set to add to Carevive's registry from real world clinical and patient reported data collected using an electronic care planning system (CPS) with remote symptom monitoring that is used…
- Conditions
- Breast Cancer, Lung Cancer, Multiple Myeloma, Ovarian Cancer
- Trial name
- NCT05974150
- Testing
- Web based survey
- Where
- 7 sites in United States
- Volunteers
- 25 people
- Sponsor
- Carevive Systems, Inc.
Multiple Myeloma
Clinical Trial of BCMA CAR T Cell Infusion in Patients With BCMA-positive r/r Multiple Myeloma
Multiple myeloma is a kind of hematological malignancy caused by the proliferation of malignant clonal plasma cells. In recent years, the emergence of new therapeutic drugs such as bortezomib and lenalidomide has significantly…
- Trial name
- NCT04186052
- Testing
- BCMA-CART cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Multiple Myeloma
A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment
The purpose of this study is to assess the safety and clinical response including overall response rate (ORR) of real-life standard-of-care (SOC) treatments under routine clinical practice, over a 24-month period, in patients…
- Trial name
- LocoMMotion (NCT04035226)
- Testing
- No intervention
- Where
- 75 sites in United States, Belgium and 8 more
- Volunteers
- 254 people
- Sponsor
- Janssen-Cilag Ltd.
Multiple Myeloma
A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of Use
To understand the safety and efficacy of Revlimid® 5 mg Capsules (hereinafter referred to as Revlimid) in patients with "relapsed or refractory multiple myeloma" (hereinafter referred to as "relapsed or refractory MM") who have…
- Trial name
- NCT02922543
- Where
- Japan
- Volunteers
- 361 people
- Sponsor
- Celgene
Multiple Myeloma
BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma
RATIONALE: Monoclonal antibodies, such as BB-10901, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- IMGN901 (NCT00346255)
- Testing
- BB-10901
- Where
- 8 sites in United States, Argentina
- Volunteers
- 37 people
- Sponsor
- ImmunoGen, Inc.
Relapsed/Refractory Multiple Myeloma, Amyloid Light-chain Amyloidosis
A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA)
This is a first-in-human (FIH) Phase 1/Phase 2 study for evaluating SAR445514 in monotherapy in participants with relapsed/refractory multiple myeloma (RRMM) and relapsed/refractory light chain amyloidosis (RRLCA).
- Trial name
- NCT05839626
- Testing
- SAR445514
- Where
- 16 sites in Australia, Belgium and 5 more
- Volunteers
- 32 people
- Sponsor
- Sanofi
Multiple Myeloma
A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
This is an open-label, multi-center, international, Phase 1/2 study to assess the safety, PK and efficacy of CC-92480 monotherapy and in combination with dexamethasone in subjects with relapsed and refractory multiple myeloma…
- Trial name
- NCT03374085
- Testing
- CC-92480, Dexamethasone
- Where
- 54 sites in United States, Australia and 9 more
- Volunteers
- 200 people
- Sponsor
- Celgene
Hematological Malignancies
A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to evaluate the efficacy of teclistamab at the recommended Phase 2 dose (RP2D).
- Trial name
- MajesTEC-1 (NCT04557098)
- Testing
- Teclistamab
- Where
- 51 sites in United States, Belgium and 9 more
- Volunteers
- 194 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma
An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma
This study is a multi-cohort, open-label, multicenter Phase 2 study to evaluate the efficacy and safety of bb2121 in participants with relapsed and refractory multiple myeloma (RRMM) (Cohort 1), in participants with RRMM who…
- Trial name
- KarMMa-2 (NCT03601078)
- Testing
- bb2121, Lenalomide, Talquetamab
- Where
- 25 sites in United States, France and 4 more
- Volunteers
- 312 people
- Sponsor
- Celgene
Multiple Myeloma
A Study of the Safety and Pharmacokinetics of MFGR1877S in Patients With Relapsed or Refractory t(4;14)-Positive Multiple Myeloma
This is a multicenter, open-label, dose-escalation study of MFGR1877S in patients with relapsed or refractory t(4;14)-positive multiple myeloma.
- Trial name
- NCT01122875
- Testing
- MFGR1877S
- Where
- 12 sites in United States, Canada
- Volunteers
- 14 people
- Sponsor
- Genentech, Inc.
Hematological Malignancies
Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to identify the recommended Phase 2 dose(s) (RP2Ds) and schedule assessed to be safe for Teclistamab and to characterize the safety and tolerability of Teclistamab at the RP2Ds.
- Trial name
- MajesTEC-1 (NCT03145181)
- Testing
- Teclistamab (IV), Teclistamab(SC)
- Where
- 13 sites in United States, France and 3 more
- Volunteers
- 302 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma
A Retreatment Study With Bortezomib for Multiple Myeloma
The purpose of this study is to monitor such factors as a past history, a previous history of drug use, the degree of response to initial treatment, the frequency of previous therapies, age, Eastern Cooperative Oncology Group…
- Trial name
- NCT01030302
- Testing
- bortezomib
- Volunteers
- 56 people
- Sponsor
- Janssen Korea, Ltd., Korea
Multiple Myeloma
CP-751,871 Treatment For Patients With Multiple Myeloma
This study represents the first-in-human study for CP-751,871. The study aimed to define the safety, tolerability, and maximum tolerated dose of CP-751,871 in patients with multiple myeloma through a dose escalation design.
- Trial name
- NCT01536145
- Testing
- CP-751,871
- Where
- 6 sites in United States
- Volunteers
- 47 people
- Sponsor
- Pfizer
Ovarian Cancer, AIDS-related Kaposi Sarcoma
Doxil/Caelyx BE Study
The aim of this study is to demonstrate the bioequivalence of DOXIL/CAELYX, 40 mg/m2 (IV infusion over 90 minutes) between two manufacturing facilities.
- Conditions
- Ovarian Cancer, AIDS-related Kaposi Sarcoma, Multiple Myeloma, Metastatic Breast Cancer
- Trial name
- NCT05567601
- Testing
- DOXIL/CAELYX
- Where
- 14 sites in India
- Volunteers
- 36 people
- Sponsor
- Baxter Healthcare Corporation
Multiple Myeloma
the Safety and Efficacy of SENL103 Autologous T Cell Injection
To observe the safety and efficacy of SENL103 cells in the treatment of patients with recurrent or refractory plasma cell blood tumors.
- Trial name
- NCT06067581
- Testing
- SENL103
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
Multiple Myeloma
A Trial of Skeletal Targeted Radiotherapy Using Holmium-166-DOTMP in Patients With Multiple Myeloma
Multiple myeloma is a disease that resides primarily in the bone and has shown to be sensitive to radiation. Administration of a radiotherapy agent that targets the bone, such as Holmium-166-DOTMP, in conjunction with melphalan…
- Trial name
- NCT00039754
- Testing
- Holmium-166-DOTMP
- Sponsor
- Poniard Pharmaceuticals
Multiple Myeloma
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
This is a phase 1, multicenter, open-label study evaluating the safety and efficacy of ruxolitinib, steroids and lenalidomide among MM patients who currently show progressive disease.
- Trial name
- NCT03110822
- Testing
- Ruxolitinib Oral Tablet [Jakafi], Lenalidomide, Methylprednisolone
- Where
- 13 sites in United States
- Volunteers
- 134 people
- Sponsor
- Oncotherapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.